Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: A comparison with quinupristin-dalfopristin

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3583-3585

  Raad, Issam I ^a   Hanna, Hend A ^a   Hachem, Ray Y ^a   Dvorak, Tanya ^a   Arbuckle, Rebecca B ^a   Chaiban, Gassan ^a   Rice, Louis B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Medical Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; RNA 23S; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; DRUG SENSITIVITY; DRUG USE; ENTEROCOCCUS FAECIUM; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RNA GENE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG UTILIZATION; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; POINT MUTATION; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 4344559769     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3583-3585.2004     Document Type: Article

References (17)

1. Birmingham, M. C., C. R. Rayner, A. K. Meagher, S. M. Flavin, D. H. Batts, and J. J. Schentag. 2003. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36:159-168.
2. Chow, J. W., S. M. Donahedian, and M. J. Zervos. 1997. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin. Infect. Dis. 24:90-91.
3. Edmond, M. B., J. F. Ober, J. D. Dawson, D. L. Weinbaum, and R. P. Wenzel. 1996. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin. Infect. Dis. 23:1234-1239.
4. Fridkin, S. K., C. D. Steward, J. R. Edwards, E. R. Pryor, J. E. McGowan, Jr., L. K. Archibald, R. P. Gaynes, and F. C. Tenover. 1999. Surveillance of antimicrobial use in United States hospitals: project ICARE Phase 2. Clin. Infect. Dis. 29:245-252.
5. Gonzales, R. D., P. C. Schreckenberer, M. B. Graham, S. Kelkar, K. Den-Besten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
6. Linden, P. K., R. C. Moellering, C. A. Wood, S. J. Rehm, J. Flaherty, F. Bompart, and G. H. Talbot for the Synercid Emergency-Use Study Group. 2001. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin. Infect. Dis. 33:1816-1823.
7. Linden, P. K., A. W. Pasculle, R. Manez, D. J. Kramer, J. J. Fung, A. D. Pinna, and S. Kusne. 1996. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin. Infect. Dis. 22:663-670.
8. Lobritz, M., R. Hutton-Thomas, S. Marshall, and L. B. Rice. 2003. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47:3318-3320.
9. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.
10. Moellering, R. C., P. K. Linden, J. Reinhardt, E. A. Blumberg, F. Bompart, and G. H. Talbot for the Synercid Emergency-Use Study Group. 1999. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 44:251-261.
11. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 32:710-721.
12. Murray, B. E., K. V. Singh, J. D. Heath, B. R. Sharma, and G. M. Weinstock. 1990. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J. Clin. Microbiol. 29:2059-2063.
13. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
14. Raad, I., R. Hachem, H. Hanna, E. Girgawy, K. Rolston, E. Whimbey, R. Husni, and G. Bodey. 2001. Treatment of vancomycin-resistant enterococcal infection in the immunocompromised host: quinupristin/dalfopristin in combination with minocycline. Antimicrob. Agents Chemother. 45:3202-3204.
15. Soltani, M., D. Beighton, J. Philpott-Howard, and N. Woodford. 2000. Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe. Antimicrob. Agents Chemother. 44:433-436.
16. Werger, G., I. Klare, and W. Witte. 1998. Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur. J. Clin. Microbiol. Infect. Dis. 17:401-402.
17. Winston, D. J., C. Emmanouilides, A. Kroeber, J. Hindler, D. A. Bruckner, M. C. Territo, and R. W. Busuttil. 2000. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 30:790-797.